Interferon Gamma for Retinal Fluid Absorption Restoration
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of Interferon gamma as a therapeutic agent to restore retinal fluid absorption.
Thermosensitive Hydrogel Bioink for Vascular Tissue Engineering
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for a thermosensitive, pro-angiogenic material designed for 3D bioprinting.
iPSC Differentiation Protocol for Fibroblast and Endothelial Cell Generation
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a novel iPSC differentiation protocol for generating fibroblasts and endothelial cells.
Myocilin Mutant Cell Lines for Glaucoma Research and Drug Screening
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative therapeutic strategies targeting myocilin mutations in glaucoma.
RS-1 Knockout Mouse Model for X-Linked Retinoschisis (XLRS) Research
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a transgenic mouse model for X-linked retinoschisis (XLRS).
Gene Therapy for Treatment of CRX-Autosomal Dominant Retinopathies
Description of Technology:
Mutations in the cone rod homeobox (CRX) transcription factor lead to distinct retinopathy phenotypes, including early-onset vision impairment in dominant Leber congenital amaurosis (LCA). Adeno-Associated virus (AAV) vector-mediated delivery of a CRX cDNA under the control of a CRX promoter region partially restored photoreceptor phenotype and expression of phototransduction genes in an in vitro model of CRX-LCA.
RP2 and RPGR Vectors For Treating X-linked Retinitis Pigmentosa
X-linked forms of retinitis pigmentosa (XLRP) are relatively severe blinding disorders, resulting from progressive photoreceptor dysfunction primarily caused by mutations in RPGR or RP2 gene.
Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration
Summary:
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an AAV2-based delivery system or an eyedrop formulation to deliver a Pigment Epithelium-Derived Factor (PEDF) peptide as a gene-agnostic approach to treating inherited retinal diseases.
MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE
Summary:
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an eyedrop formulation to deliver a series of peptides as a gene-agnostic approach to treating inherited retinal diseases.
Electrochemical Impedance Spectroscopy (EIS) for Non-Destructive Assessment of Epithelial Integrity
This technology includes a novel apparatus and method that utilizes Electrochemical Impedance Spectroscopy (EIS) to assess the integrity of epithelial cell membranes non-destructively. By applying frequency-modulated voltage signals and facilitating fluid exchange on both sides of the epithelial tissue, this technology allows researchers to characterize membrane-specific responses with unprecedented accuracy.